At a glance
- Mechanism of action
- Mitochondrial peptide: activates the energy sensor AMPK - the same state as intense exercise or fasting - and signals the cell to burn fat and produce new ATP.
- Benefits & use
- Said to improve endurance, metabolic flexibility and insulin sensitivity; nicknamed "exercise in a bottle" in biohacking.
- Study status
- Level 2: the spectacular effects come mainly from animal studies; the first human trials (Phase 1/2) are just beginning.
- Dosing note
- Experimental, vials 10–40 mg, subcutaneous. No dosing instructions - information only.
MOTS-c is a mitochondrial peptide that activates the energy sensor AMPK - the same state as intense exercise or fasting. It is therefore nicknamed "exercise in a bottle". Evidence level 2 (experimental).
How does MOTS-c work?
Unlike the GLP-1 injections, MOTS-c acts directly inside the mitochondria, the "power plants" of the cell. It switches on AMPK, which signals the cell to burn fat and build new ATP. The focus is on cellular energy efficiency, not appetite. This positions MOTS-c very differently from metabolic drugs such as semaglutide, which work through the gut-brain axis instead of the mitochondria.
What is MOTS-c used for?
Experimentally, it is used to boost endurance, restore metabolic flexibility and counter age-related insulin resistance - popular in biohacking and anti-aging circles. People often stack it conceptually with regeneration peptides such as CJC-1295 / Ipamorelin. Want to track what you try over time? Create a free account.
What does the evidence say?
The spectacular effects come mainly from animal studies; in humans the evidence is still weak. The first early human trials (Phase 1/2) are under way. Approval is a long way off. For reconstitution and volume questions, see the FAQ and the dosage calculator.
Note: Educational information, not medical advice. Many of these substances are experimental and not approved for human use.
Related peptides
Sources
- Overview of mitochondrial peptides - ClinicalTrials.govhttps://clinicaltrials.gov